Whitehawk Therapeutics, Inc. — Director's Dealing 2021

Aug 31, 2021

SEC Form 4/A — Form 4/A

Issuer: Aadi Bioscience, Inc. (AADI)
CIK: 0001422142
Period of Report: 2021-08-26

Reporting Person: Dalal Anupam (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-26	Common Stock	P	1529402	$13.077	Acquired	1529402	Indirect

Footnotes

F1: Consists of (i) 1,284,698 shares held by Acuta Capital Fund, LP ("Acuta Capital") and (ii) 244,704 shares held by Acuta Opportunity Fund, LP. ("Acuta Opportunity Fund"). Acuta Capital Partners, LLC ("Acuta Partners") is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Managing Member of Acuta Partners. The Reporting Person has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and the Reporting Person disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein.

F2: This amendment is filed to correct footnote (1) included in the Form 4 filed August 30, 2021.